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Abstract
Development of an effective vaccine against human cytomegalovirus (HCMV) is a need of
utmost medical importance. Generally, it is believed that a live attenuated vaccine would
best provide protective immunity against this tenacious pathogen. Here, we propose a strat-
egy for an HCMV vaccine that aims at the simultaneous activation of innate and adaptive
immune responses. An HCMV strain expressing the host ligand ULBP2 for the NKG2D
receptor was found to be susceptible to control by natural killer (NK) cells, and preserved
the ability to stimulate HCMV-specific T cells. Infection with the ULBP2-expressing HCMV
strain caused diminished cell surface levels of MHC class I molecules. While expression of
the NKG2D ligand increased the cytolytic activity of NK cells, NKG2D engagement in CD8+
T cells provided co-stimulation and compensated for lower MHC class I expression. Alto-
gether, our data indicate that triggering of both arms of the immune system is a promising
approach applicable to the generation of a live attenuated HCMV vaccine.
Author Summary
Human cytomegalovirus (CMV) is a major cause of morbidity and mortality in congeni-
tally infected newborns and immunocompromised individuals, indicating an utmost need
for a vaccine to protect these vulnerable groups. Recent experimental studies in animal
models, including non-human primates, have shown that attenuated CMVs trigger a
potent immune response and are attractive vaccine candidates. However, an effective
CMV vaccine is still not available. Here, we demonstrate that rational engineering of a live
attenuated human CMV vaccine candidate is feasible. We equipped a CMV strain with an
immunostimulatory molecule that is a ligand for an activating receptor present on both
Natural Killer cells and CD8+ T cells. Moreover, we deleted several immunoevasins
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involved in downregulation of MHC class I molecules and of a ligand for Natural Killer
cells in order to elicit stronger immune responses. In vitro assays using human immune
cells and a first assessment in a humanized mouse model in vivo suggest that the generated
CMV strain is attenuated and has the ability to induce a virus-specific immune response.
Our study proposes this novel approach for the development of a rationally engineered
CMV vaccine.
Introduction
Human cytomegalovirus (HCMV) is a highly prevalent herpesvirus infecting most of the
human population [1, 2]. In immunocompetent individuals infection is usually asymptomatic,
yet results in the establishment of latency. However, HCMV is the leading cause of congeni-
tally related diseases causing severe and often irreparable birth defects [3–5]. HCMV is also
the most common opportunistic infection causing morbidity in immunocompromised
patients [6–8]. Due to the high economic and health burden, development of an HCMV vac-
cine has key public health priority [9, 10].
Vaccination of adolescents, or ideally of all children at young age, would be the most effec-
tive strategy to reduce the incidence of congenital CMV infection [11]. The immune correlates
preventing transmission of CMV across the placenta are not completely defined yet; however,
it seems likely that both humoral and cellular immunity are contributing to protection. Vacci-
nation of immunocompromised transplant recipients would be more challenging, because of
lower ability to mount immune responses and also due to safety concerns; nonetheless, at least
in solid organ transplant patients, inducing or boosting immunity before transplantation
would be feasible and promising. However, in both settings, clinical trials with subunit vac-
cines were only partially efficacious in preventing infection [12, 13]. Humoral and cellular
immunity can more effectively be achieved by application of a live vaccine. Indeed several pre-
clinical studies in animal models, including in non-human primates, revealed a robust capacity
of attenuated CMVs to elicit a potent memory T cell response [14–20].
With the exception of the well-established Oka vaccine that provides excellent protection
against varicella-zoster virus, no attenuated vaccine against other herpesviruses has been
approved. There are several difficulties that hamper the development of an effective live
HCMV vaccine. The ability of HCMV to reactivate and to re-infect seropositive individuals
indicates that immunity resulting from primary infection cannot completely prevent subse-
quent infections [21–25]. Another challenge is to accomplish an adequate balance between
safety and immunogenicity. For instance, a live HCMV vaccine based on the Towne strain
could not prevent infection of renal transplant recipients, but lowered severity of CMV disease
[26, 27], suggesting that this vaccine strain was over-attenuated. Thus, there is a need to ratio-
nally engineer an HCMV vaccine that induces comparable or ideally better immunity than
natural infection and at the same time presents an excellent safety profile. One approach is the
generation of chimeras between the Towne and Toledo strains and these are currently investi-
gated in clinical trials [28, 29].
Numerous viral encoded immunoevasins prevent the development of full-blown CMV-spe-
cific immunity. Accordingly, genetically modified animal CMVs lacking immunoevasins
exhibited outstanding vaccine properties in mouse and guinea pig models [30, 31]. Recently,
we found that a mouse CMV (MCMV) expressing a host ligand for the activating receptor
NKG2D induces an efficient CD8+ T cell response despite being profoundly attenuated [15,
ULBP2-Expressing HCMV Strain
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32]. Moreover, challenge infection experiments indicated that the protection obtained after
immunization is superior to the one seen after natural infection [15, 32].
It is highly desirable to test the suitability of similar approaches for a recombinant HCMV
vaccine. However, the strategy successfully established for MCMV cannot simply be translated
to HCMV. Divergence between rodents and primates started ~90 million years ago and
resulted in some differences of the immune system of mouse and man [33]. Similarly, co-evo-
lution with the respective hosts led to even larger dissimilarity of viral virulence factors [34,
35].
In this study, we report on the construction and evaluation of a recombinant HCMV strain
expressing the host ligand ULBP2 for the NKG2D receptor. We found that cells infected with
the ULBP2-expressing strain increased the cytolytic activity of NK cells in an NKG2D-depen-
dent manner, thereby preventing viral spread and containing the viral infection to few cells.
Still, the strain exhibited a robust capacity to activate HCMV-specific T cells. Interestingly, the
mechanisms steering T cell activation turned out to be different for the viral strains. Alto-
gether, our data imply that the chosen strategy allows attenuation of an HCMV strain, while
retaining its ability to stimulate innate NK cell and adaptive T cell immunity.
Results
The ULBP2-expressing HCMV strain enhances NK cell-mediated
cytotoxicity, limiting viral spread
To generate an HCMV strain for testing a novel vaccination approach that aims at activation
of NK cells as well as T cells we used the bacterial artificial chromosome (BAC)-cloned strain
TB40/E (herein referred as TB40) [36] that displays several features useful for vaccine develop-
ment. In contrast to most other HCMV isolates, after extended passages in fibroblasts TB40
retains a complex of the glycoproteins gH/gL/UL128-UL131A (called pentameric complex) on
the envelope of its virion important for broad cell tropism and produces a high rate of cell free
virus, ultimately facilitating large scale production under GMP conditions [36]. TB40 lacks the
immunoevasins US2, US3 and US6 [36] involved in MHC class I downregulation, which is
expected to improve antigen presentation and priming of the CD8+ T cell response [37]. Note
that US11 –another MHC class I immunoevasin–is retained. In order to attenuate the virus
(named ULBP2-TB40) and to render it sensitive to NK cell control we inserted the gene for
the host NKG2D ligand ULBP2 in the viral genome and replaced UL16, which normally inter-
feres with expression of NKG2D ligands in infected cells [38–40] (Fig 1A). The other NK cell
evasion genes present in the parental strain [36] were retained. Insertion of the ULBP2 open
reading frame (ORF) had no influence on the viral growth kinetics in vitro (S1 Fig). In human
foreskin fibroblasts (HFF) infected with ULBP2-TB40, strong ULBP2 surface expression was
observed, whereas in cells infected with the parental strain TB40 no ULBP2 could be detected
(Fig 1B). Expression of ULBP2 in HCMV infected cells led to substantially increased lysis by
NK cells (for all donors tested) when compared to cells infected with TB40 (Fig 1C and 1D).
Blocking of the NKG2D receptor with a specific antibody indicated that for NK cells of all
donors analyzed the observed gain of cytotoxicity against ULBP2-TB40 infected cells was
mediated via an NKG2D-dependent mechanism (Fig 1D). To determine the effect of the
improved NK cell response on viral spread, we compared the ability of primary human NK
cells to control the transmission of the viruses from infected to non-infected neighboring cells
by applying a focus expansion assay [41]. NK cells could limit the spread of the TB40 virus as
reported previously [41]. However, spread of the ULBP2 expressing strain was markedly more
inhibited leading to less infected cells per focus of infection (Fig 1E) as well as a lower number
of infectious foci in cell cultures (S2 Fig). Blocking of the NKG2D receptor with antibodies
ULBP2-Expressing HCMV Strain
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reduced the NK cell control of ULBP2-TB40 to the level observed for TB40 (Fig 1F), confirm-
ing that the observed additional gain of control is mediated by an NKG2D-dependent mecha-
nism. Taken together, viral expression of ULBP2 leads to increased NK cell-mediated
cytotoxicity that limits viral spread.
Fig 1. Spread of the ULBP2-expressing HCMV strain is strongly controlled by NK cells. (A) The ULBP2-TB40 strain was generated by insertion of
a ULBP2 expression cassette (driven by the mouse CMV major immediate-early promoter (mMIEP)), replacing ORF UL16 in the BAC-cloned TB40
genome that lacks also the US1 to US6 region. (B) HFF were infected at an MOI of 1 with TB40 or ULBP2-TB40 or left uninfected. The infection rate at
day 1 p.i. was determined by flow cytometry following intranuclear staining with an IE1/2-specific antibody. Lower panels, ULBP2 surface expression on
uninfected, TB40 (black lines) or ULBP2-TB40 infected cells (red line). Grey fill, isotype control. (C) Cytotoxicity assays were set up at the indicated
effector/target (E/T) ratios with primary NK cells and uninfected (white circles), TB40 (black circles) and ULBP2-TB40 (red circles) infected HFF (MOI 1,
1 d.p.i.). Results are means ± SEM of 3 independent experiments performed with NK cells of one donor. (D) Compiled data of cytotoxicity assays
performed with NK cells from 3 HCMV-negative donors as in (C), and in addition with ULBP2-TB40 infected target cells in the presence of an NKG2D
blocking antibody (aNKG2D) or isotype antibody (iso). Results are medians (with range) of specific lysis at E/T ratio 8:1 (n = 3 donors). Data were
compiled from 3 independent experiments. (E) Focus expansion assays using TB40 or ULBP2-TB40 infected HFF and primary NK cells. At day 3 of co-
culturing infected cells were detected by fluorescence microscopy following staining with an IE1/2 antibody. Graph displays cumulative data as medians
(with range) of experiments done with NK cells of 6 donors. A focus of infection is defined as a cluster of 3 to 60 infected cells. Four wells were analyzed
per donor and all infectious foci were counted with 2 to 8 foci being present per well. Images are from one representative experiment. (F) Focus
expansion assays were carried out as described in (E) and additionally in the presence of NKG2D blocking (aNKG2D) or isotype antibodies (iso) using
NK cells from 4 donors. Statistical analysis for (C) (NK cell-mediated cytotoxicity assay at E/T ratio 16:1) was done with two-way ANOVA with Bonferroni
correction and for (E, F) with Mann-Whitney t-test. *, P < 0.05, **, P < 0.01, ***, P < 0.001.
doi:10.1371/journal.ppat.1006015.g001
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A first in vivo assessment of the ULBP2-TB40 strain in humanized mice
Mice reconstituted with human hematopoietic stem cells can serve as models for infection
with several human-specific viruses [42, 43] and the use of such a model has also been reported
for HCMV [44]. Thus, to assess whether the ULBP2-TB40 strain can induce an immune
response in vivo we performed infection experiments in humanized mice. For a pilot experi-
ment NOD/SCID/IL2Rcγc mice expressing human HLA-A02:01 molecules and engrafted
with fetal liver-derived human CD34+CD38- hematopoietic stem cells (humanized NSG-A2
mice) were injected with HCMV-infected fibroblasts as described [44]. Although viral DNA
could be detected in spleens of infected animals, we did not find hints for the generation of
HCMV-specific CD8+ T cells, probably due to only low numbers of human myeloid cells pres-
ent in these mice [45]. Thus, for subsequent experiments we injected humanized mice with
uninfected or TB40 or ULBP2-TB40 infected DC (Fig 2A). Human CD3+ T cells present in
periarteriolar lymphoid sheaths (PALS) were found in spleens at day 18 p.i., when the human-
ized NSG-A2 mice were sacrificed and organs examined, irrespectively on whether mice were
injected with uninfected or infected DC (Fig 2B). The frequency of human CD8+ and CD4+ T
cells, as well as of CD19+ B cells and CD56+ NK cells in spleens was in a similar range for the
groups receiving infected DC (Fig 2C). In livers slightly higher frequencies of NK cells were
detected in the group receiving ULBP2-TB40 infected DC than in the group receiving
TB40-infected DC (although the differences were not significant) (S3A Fig). Immunopheno-
typing of the NK cells in spleen revealed that mice injected with ULBP2-TB40 infected cells
had a higher percentage of CD57+ NK cells when compared to mice receiving the parental
virus TB40 (S3B Fig). Moreover, in some mice injected with ULBP2-TB40 DC IFNγ-express-
ing NK cells were found (S3C Fig). The CD57 marker is expressed on mature NK cells [46, 47]
and the detection of IFNγ producing NK cells suggests that they were functional.
CMV-specific antibodies appear particularly important for prevention of congenital infec-
tion [48]. We therefore examined the ability of the ULBP2-TB40 strain to mount a humoral
immune response. Although NSG humanized mice are not ideal for analyzing antibody
responses [49, 50], CMV-specific IgM antibodies were detected at comparable levels in the
serum of both groups following immunization with either strain (Fig 2D). We concluded that
the ULBP2-TB40 strain elicits CMV-specific antibodies with similar efficiency as the TB40
strain.
Finally, we investigated whether CMV-specific T cells were primed in the humanized mice.
When examined at day 14 p.i., CD8+ T cells specific for the HCMV epitopes NLVPMVATV
and VLEETSVML (derived from the viral proteins pp65 and IE1) were found in blood of sev-
eral animals (S4 Fig). Moreover, HCMV-specific CD8+ T cells were also detected in spleens at
day 18 p.i. (Fig 2E and S5A Fig). The percentage of IE1-specific CD8+ T cells was comparable
between both infected groups (Fig 2E), and this applied also to the absolute numbers of
IE1-specific CD8+ T cells (S5A Fig). IFNγ positive CD8+ T cells could be detected at low level
in few animals (S5B Fig) following stimulation with a specific peptide, confirming priming of
IE1-specific CD8+ T cells. The majority of the CD8+ T cells displayed a phenotype of termi-
nally differentiated effector memory (TEMRA) cells (S5C Fig), independently of the treatment
applied.
To investigate to which extent the two strains can establish infection in the humanized ani-
mals, viral loads were measured in several organs on day 18 p.i. using quantitative PCR
(qPCR). Viral DNA was found only in spleens of infected animals, and not in the other organs
analyzed. In spleen of most of the animals infected with the TB40 virus viral DNA was detected
(Fig 2F), whereas in the animals of the ULBP2-TB40 infected group the viral DNA loads were
lower, although the difference in the viral loads was not statistically significant. Taken together,
ULBP2-Expressing HCMV Strain
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Fig 2. Immunogenicity of the ULBP2-TB40 strain in humanized mice. (A) Experimental design for immunization of humanized mice
with the HCMV strains. DC generated from HLA-A2+ HCMV-negative donors were infected or left uninfected and 1 day p.i. injected into
NSG-A2 humanized mice. Mice were boosted 7 days later in the same manner. On day 18 p.i. mice were sacrificed and the frequency of
HCMV-specific CD8+ T cells and viral load were analyzed. (B) Representative immunohistological images of spleens from one animal of
each group after staining with a CD3 antibody. Scale bar, 200 μm. (C) Percentages of human CD8+ and CD4+ T cells out of total CD3
+ cells and of CD19+ B cells and CD56+ NK cells (right y-axis in red) out of total CD3- cells in spleens of animals from the uninfected group
(white circles), or groups receiving TB40 (black circles) and ULBP2-TB40 infected DC (red circles). (D) CMV-specific IgM antibodies in
serum of infected animals detected by ELISA. (E) Percentage of IE1-tetramer+ CD8+ T cells in spleens of animals for the indicated groups.
(F) Viral load in spleen at day 18 p.i. Each circle represents the result for one animal and lines indicate medians. Data from all panels was
analyzed using the Mann-Whitney t-test. *, P < 0.05. ns, P > 0.05.
doi:10.1371/journal.ppat.1006015.g002
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we concluded that the ULBP2-TB40 virus is able to prime HCMV-specific CD8+T cells and
induce CMV-specific antibodies in humanized mice to a similar extent as the TB40 strain
despite low viral loads.
The ULBP2-TB40 strains retains the ability to stimulate virus-specific
CD8+ T cells and other immune effector cells
Encouraged by the observation that the ULBP2-TB40 strain could prime CD8 T cells in the
humanized mice, we further investigated the activation of CMV-specific T cells by DC infected
with this strain. It is well known that HCMV inhibits maturation of infected DC [51–53], and
since DC are central for stimulation of T cells, it was important to know how the ULBP2-TB40
virus influences this process. In particular it was hard to predict whether expression of ULBP2
in HCMV infected DC increases the CD8+ T cell response by engaging the costimulatory
NKG2D receptor [54, 55], or whether it would perhaps lead to T cell exhaustion [56]. To test
the ability of TB40 and ULBP2-TB40 infected DC to expand HCMV-specific CD8+ T cells,
primary CD8+ T cells isolated from HLA-A02:01 HCMV-seropositive healthy donors were
co-cultured with infected autologous monocyte-derived DC or for control with uninfected DC
(Fig 3). Mature DC loaded with the HLA-A02:01 specific immunodominant peptide NLVPM
VATV derived from the pp65 protein were used as a positive control (S6 Fig). DC infected
with either of the two viruses induced a comparable percentage of pp65-specific CD8+ T cells
(Fig 3A). When tested against pp65 peptide-loaded DC, the pp65-specific CD8+ T cells had
comparable cytokine production and degranulation capacity (Fig 3B). The simultaneous mea-
surement of IFNγ, TNFα and degranulation allowed us to determine the multifunctionality of
the pp65-specific CD8+ T cells, revealing that there was a trend toward higher multifunction-
ality of the T cells that were expanded with ULBP2-TB40 infected DC (Fig 3C), although the
differences were not statistically significant. Expansion with ULBP2-TB40 infected DC
resulted in a lower percentage of CD8+ T cells with central memory phenotype than expansion
with pp65-peptide loaded DC (S7A Fig). Both viruses induced similar percentages of effector
memory and central memory CD8+ T cells and of antigen-specific CD8+ T cells (S7A and S7B
Fig). The frequency of exhausted PD-1+ CD8+ T cells after expansion with DC infected with
either virus was in the same range (10 to 30% of total CD8+ T cells) (S7C and S7D Fig). Over-
all, we concluded that ULBP2-TB40-infected DC induced a comparable percentage and quality
of HCMV-specific CD8+ T cells as TB40-infected DC.
NK cells have the ability to modulate the outcome of T cell responses against CMV [57, 58].
They can influence activation of CMV-specific T cells in a positive manner by providing an
appropriate microenvironment and by lysis of infected cells, thereby increasing the amount of
available antigens [59, 60]. In contrast, NK cells can potentially also limit the activation of T
cells by eliminating CMV infected DC [61, 62]. Since expression of the ULBP2 molecule by
ULBP2-TB40 led to strong NK cell-mediated lysis of infected cells (compare Fig 1), it was
important to analyze the effect of NK cells on the induction of T cell responses. To this end, we
set up autologous stimulation assays using peripheral blood mononuclear cells (PBMC).
PBMC isolated from HCMV-seropositive donors were co-cultured with autologous mono-
cyte-derived DC either uninfected or infected with the respective viruses or–for control–
matured and loaded with pp65 peptides. The infection rate of the DC was comparable for both
viruses (S8A Fig). Activation of NK cells as assessed by intracellular cytokine staining for
proinflammatory cytokines (IFNγ+, TNFα+) and degranulation (CD107a+) was in a similar
range for cultures containing either ULBP2-TB40 or TB40-infected DC (Fig 4A). Likewise, the
percentage of CD8+ T cells producing IFNγ+ and degranulating (CD107a+) was comparable
upon co-cultivation with TB40 or ULBP2-TB40 infected DC (Fig 4B). Similar results were
ULBP2-Expressing HCMV Strain
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Fig 3. Ex vivo expansion with ULBP2-TB40 infected DC results in highly functional HCMV-specific CD8+ T cells. (A) Dot plots of an
experiment performed with cells from one donor indicating percentage of pp65-specific CD8+ T cells before expansion and after 14 days of co-culture
with TB40 or ULBP2-TB40 infected DC. Graph displays compiled data for four donors as percentages of pp65-specific CD8+ T cells expanded with
ULBP2-Expressing HCMV Strain
PLOS Pathogens | DOI:10.1371/journal.ppat.1006015 December 1, 2016 8 / 27
obtained for CD4+ T cells–ULBP2 expression did not impair the ability of CD4+ T cells to
produce proinflammatory cytokines (IFNγ and TNFα) in response to infected DC (S8B and
S8C Fig). In summary, PBMC co-cultures with ULBP2-TB40 infected DC activated CD8+ and
CD4+ T cells as well as NK cells to the same extent as TB40-infected DC and most importantly,
ULBP2 expression in the infected DC did not impair the stimulation of the immune effector
cells.
The ULBP2-TB40 strain causes stronger MHC class I downregulation in
infected cells
Previous studies suggested that ULBP2 can co-stimulate CD8+ T cells via the NKG2D receptor
[54]. In order to understand how ULBP2-TB40 infected DC activate CD8+ T cells, we first
analyzed the maturation phenotype of the DC. Maturation of HCMV-infected DC in terms of
CD80, CD86 and HLA DR expression was found to be impaired–as described by others [51–
53]–to the same extent for both viruses (S9 Fig). Interestingly, HLA class I downregulation was
more pronounced in ULBP2-TB40 infected DC (Fig 5A and 5B), which became particularly
obvious when the surface expression level of HLA-A02:01 molecules was analyzed (Fig 5A and
5B, bottom panels). To attribute this phenotype to the individual genetic alterations intro-
duced into the ULBP2-TB40 strain, we performed infection experiments with different viruses.
In particular, we included the original TB40/E strain (referred to as TB40/E WT), harboring a
complete complement of the MHC immunoevasins (US2, US3, US6, US11), and the strain
dUL16 TB40 that lacks ORF UL16 as well as ORFs US1 to US6. When analyzed 1 and 2 days
post infection (p.i.) the strongest HLA-I downregulation was observed for TB40/E WT
infected fibroblast (Fig 5C), substantially more pronounced than in TB40-infected cells,
reflecting the effect of the US2 to US6 genes on HLA-I surface expression. Remarkably, HLA-I
downregulation in ULBP2-TB40 infected cells was as strong as in cells infected with the
TB40E WT strain (Fig 5C, compare second panel and bottom panel), indicating an additional
effect of ULBP2 expression (Fig 5C, bottom panel on the right). The dUL16 TB40 virus
induced an intermediate phenotype (Fig 5C, second last panel), most likely due to upregula-
tion of ULBP2 as a consequence of missing UL16 (Fig 5C, second last panel on the right). The
degree of HLA-I downregulation in dUL16 TB40 and ULBP2-TB40 infected cells correlated
with ULBP2 expression on the surface of these cells (Fig 5C). Intriguingly, plotting of HLA
class I and ULBP2 surface expression for ULBP2-TB40 infected cells indicates that there is an
inverse relationship of the expression of these molecules (Fig 5D). Taken together, these results
show that expression of the NKG2D ligand ULBP2 increases MHC class I down-regulation in
HCMV-infected cells.
ULBP2 triggers loss of NKG2D from the surface of HCMV-specific T
cells
The observed lower surface expression of HLA-I molecules in ULBP2-TB40 infected cells was
expected to impair antigen presentation, leading to less CD8+ T cell activation than upon
uninfected (white circles), TB40 (black circles) and ULBP2-TB40 (red circles) infected DC. Data obtained with cells from individual donors are
connected by lines. (B) Cytokine production and degranulation of pp65-specific CD8+ T cells (obtained as described in (A) or upon co-culture
with pp65 peptide-loaded DC (pp65-mDC)) in response to pp65 peptide-loaded DC as target cells. Representative staining for IFNγ, TNFα and
CD107a of pp65-specific CD8+ T cells obtained from one donor. The graphs at right are compiled data for 4 donors. (C) Multifunctionality of the
expanded pp65-specific CD8+ T cells. Multifunctional subsets were determined using Boolean analysis based on the simultaneous measurement of
IFNγ, TNFα and CD107a positive cells. Pie charts denote the proportion of pp65-specific CD8+ T cells having 1, 2 or 3 functions for 4 different
donors. Data are representative of one out of two independent experiment performed. Statistical analysis was done with one-way ANOVA Friedman
test followed by Dunn’s Multiple Comparison test. *, P < 0.05.
doi:10.1371/journal.ppat.1006015.g003
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stimulation with TB40-infected cells. However, this was in contrast to the results presented in
Figs 3 and 4. To investigate this puzzle, we decided to examine in more detail the role of
ULBP2 in T cell activation. To this end, we took advantage of a CD8+ T cell clone [63] specific
for the peptide NLVPMVATV of the HCMV antigen pp65 (pp65-CTL) and co-cultured it
with ULBP2-TB40 or TB40 infected DC. We noticed that a comparable percentage of
the pp65-CTL became activated as assessed by IFNγ and TNFα intracellular cytokine staining,
independent of which virus was used for the infection of DC (Fig 6A). In addition, comparable
results were observed for the degranulation capacity (CD107a) of the pp65-CTL (Fig 6A). Data
were confirmed with DC derived from three different donors. Next, we analyzed the expres-
sion of NKG2D on the surface of the pp65-CTL. Whereas the majority of the pp65-CTL
expressed NKG2D when co-cultured with uninfected or TB40 infected DC, NKG2D surface
expression was strongly diminished in the presence of ULBP2-TB40 infected DC (Fig 6B). The
finding was confirmed with pp65-specific CD8+ T cells obtained by expansion with pp65-pep-
tide loaded DC (S10A and S10B Fig). We conclude that although the outcome in terms of T
cell activation is similar for DC infected with either strain, the underlying activating mecha-
nism is different for T cells co-cultivated with ULBP2-TB40 infected DC and involves the
NKG2D receptor as indicated by its strong, almost complete downregulation.
Discussion
In this report we propose a novel vaccination strategy that can be applied to the development
of an HCMV vaccine. The ULBP2 ligand for the NKG2D receptor that is present on both NK
and CD8+ T cells was expressed by an HCMV strain with the intention to stimulate innate as
well as adaptive immunity. We investigated the properties of the resulting recombinant
HCMV strain by in vitro assays using ex vivo-derived primary human immune cells and pro-
vide a first in vivo assessment in a humanized mouse model.
An important goal in development of a live vaccine is attenuation. To this end, we endowed
the HCMV strain with the ULBP2 gene, encoding a ligand for the activating NKG2D receptor
of NK cells, and deleted the viral gene UL16, which normally counteracts the surface exposure
of ULBP2 as well as of several other NKG2D ligands [38, 40]. This secured that there is no
interference with ULBP2 expression and, even in the unlikely case that the ULBP2 gene is acci-
dentally inactivated, the HCMV strain will remain susceptible to NK cell control. Although
NK cells are well known for their contribution to contain acute HCMV infection, these innate
immune cells cannot deploy their full efficacy because a series of NK cell evasion functions
encoded by wild-type HCMV strains dampen their activity [64]. UL16 it is one of the impor-
tant immunoevasins, which confers NK cell resistance of HCMV infected cells [39, 40]. By
breaking NK cell evasion, cells infected with the ULBP2-expressing HCMV strain were
expected to become highly vulnerable to recognition and elimination by NK cells. This was
exactly what we observed when we performed cytotoxicity assays (Fig 1C and 1D). Conse-
quently, spread of the ULBP2-expressing viral strain was strongly limited in the presence of
NK cells (Fig 1E and 1F). These data suggest that the attenuation of the ULBP2-expressing
Fig 4. T cell activation with ULBP2-TB40 infected DC is not impaired in the presence of NK cells.
Intracellular cytokine staining (IFNγ/TNFα or IFNγ) and degranulation (CD107a staining) of (A) NK cells
(CD3-CD56+) and (B) CD8+ T cells (CD3+CD8+) upon co-cultivation of PBMC from one donor with
autologous monocyte-derived DC treated or infected as indicated. Graphs on the right are compiled data of
experiments performed with cells of 4 HCMV-seropositive donors. Data generated with cells of individual
donors are connected by lines and are representative of one of three independent experiment performed.
Statistical analysis was done with one-way ANOVA Friedman test followed by Dunn’s Multiple Comparison
test. *, P < 0.05.
doi:10.1371/journal.ppat.1006015.g004
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Fig 5. ULBP2-TB40 infected cells have lower MHC class I surface expression than TB40 infected cells. (A,B)
Representative plots showing HLA class I expression using pan-HLA-A,B,C antibody (HLA I) or HLA-A02:01 antibody labeling
of infected (IE1/2+) DC. Graphs provide (A) percentage and (B) median fluorescence intensity (MFI) of HLA class I positive
uninfected immature DC (imDC) (white circles), or TB40 (black circles) and ULBP2-TB40 (red circles) infected DC of 4 to 6
donors. Horizontal bars represent medians. Data were analyzed with Mann-Whitney t-test. *, P < 0.05. (C) Representative
staining for HLA class I on uninfected HFF or HFF infected with 1 PFU/cell of the indicated viruses at day 1 or 2 p.i. The
histograms on the right depict ULBP2 expression on TB40, dUL16 TB40 (grey) or ULBP2-TB40 infected cells (red) at the
indicated time points p.i. Black line, isotype controls. (D) HLA class I and ULBP2 staining gated on ULBP2-TB40 infected
fibroblasts (IE1/2-positive cells) derived from two different donors.
doi:10.1371/journal.ppat.1006015.g005
Fig 6. HCMV-specific CTL activated by ULBP2-expressing infected DC strongly downregulate NKG2D. (A) Representative staining
of pp65-CTL for IFNγ, TNFα and CD107a after co-culturing with infected DC derived from one donor. Graphs represent compiled data for 3 donors
as percentages of IFNγ, TNFα and CD107a positive pp65-CTL after co-culturing with uninfected DC (white circles), with DC infected with TB40
(black circles) or ULBP2-TB40 (red circles) or with pp65-peptide loaded DC (NLV-DC; grey circles). Bars represent medians. (B) Flow cytometry
analysis of NKG2D expression on pp65-CTL after co-culturing with uninfected or TB40 or ULBP2-TB40 infected DC. Representative plots for one
out of three donors analyzed. Data are representative of one of two independent experiment performed.
doi:10.1371/journal.ppat.1006015.g006
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HCMV strain will not depend on pre-existing immunity against HCMV, but on the presence
of NK cells. Indeed, we detected human NK cells in the humanized mice which could contrib-
ute to the low viral load observed in animals receiving the ULBP2-expressing viral strain. This
is supported by the fact that in a humanized mouse model for Epstein–Barr virus (EBV)
human NK cells were capable to control the infection [65]. One difference between the EBV
and HCMV infection models is that B cells in humanized mice support productive EBV infec-
tion, whereas important target cells of productive HCMV infection such as human hepato-
cytes, endothelial and epithelial cells are missing [66] and thus, primarily a latent HCMV
infection is established at low level in few myeloid cells present in these animals [44]. Such lim-
itations hamper the investigation of HCMV-specific immune responses in humanized
NSG-A2 mice [67]. We found it nevertheless interesting that there was a trend towards a
higher frequency of mature CD57+ NK cells in humanized mice receiving the ULBP2-TB40
strain when compared to the group receiving TB40. Emergence of a subset of CD57+ NK cells
occurs in humans during primary HCMV infection [46]. Whether the observation for the
CD57+ NK cells points to a stronger expansion in mice injected with the ULBP2-TB40 strain
warrants further investigation. Similarly encouraging was the detection of CMV-specific IgM
antibodies and a comparable frequency of B cells and CD4+ T cells as well as CMV-specific
CD8+ T cells in mice receiving the ULBP2-TB40 and TB40 strains. Humoral immunity is one
of the important factors in preventing congenital CMV infection and thus it is essential that a
CMV vaccine can also provoke a strong antibody response. NSG mice transplanted with HSC
are not ideal for analyzing humoral immunity. In several publications impaired antibody
responses were reported [49], and only low levels of IgM were seen and no IgG [50] as in our
study. Despite this constraint, our results indicate that ULBP2 expression by the ULBP2-TB40
strain does not interfere with the ability to elicit an IgM response. Induction of CMV-specific
IgG antibodies must be analyzed in the future in novel humanized models that support anti-
body isotype switching [68–70]. We assess the observed HCMV-specific T and B cell responses
as very promising results, particularly in view of the low load of ULBP2-TB40 genomes in the
humanized mice. However, our study can only provide a first assessment of the vaccination
approach with the ULBP2-TB40 strain, and further investigation of the protective capacity of
the immune response has to await the establishment of improved humanized mouse models
for HCMV infection. As recently pointed out by Crawford et al. (2015) [67], BLT (bone mar-
row/liver/thymus) humanized mice [71, 72] may allow to reproduce acute HCMV infection
and analysis of the specific immune responses much better.
Although attenuation is a central objective concerning safety of a live vaccine, too much
attenuation could impair immunogenicity. Rapid control of the vaccine strain may for
instance limit the production of viral antigens–below a level necessary for priming of the adap-
tive T cell response. To circumvent this problem, we chose an HCMV strain that lacked several
of the MHC immunoevasins. Such strains modulate antigen presentation to a lesser extent
than HCMV isolates expressing the full complement of immunoevasins [73, 74]. In view of
these considerations, we value the comparable activation and proliferation of HCMV-specific
T cells observed upon co-cultivation with ULBP2-TB40 and TB40 infected DCs (Figs 3 and
4C) as a positive result. As a matter of fact, we expected a stronger CD8+ T cell response,
because there was a second reason to express ULBP2 by the HCMV strain. It has been reported
that NKG2D - besides being an activating receptor on NK cells—is also a co-stimulatory recep-
tor expressed on CD8+ T cells [54, 75]. Indeed, when we co-cultured HCMV-specific T cells
with ULBP2-TB40 infected DC, strong downregulation of NKG2D was observed (Figs 6B and
S10B Fig). This did not occur when the T cells were co-cultured with uninfected or TB40-in-
fected DC. We concluded therefore that reduced NKG2D surface expression reflects triggering
of the receptor in the T cells. Regulation of NKG2D expression has been described as a
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physiologic mechanism [76] and therefore NKG2D downregulation in our assays should not
be misinterpreted as a negative effect as previously suggested [77–79]. Along the same line, we
observed that the HCMV-specific T cells that we obtained in the expansion assays expressed
high levels of NKG2D (S11 Fig), suggesting that initial NKG2D downregulation is transient
and rather indicates co-stimulation and activation of the T cells.
The seemingly neutral outcome of ULBP2 expression with respect to the frequency of acti-
vated CD8+ T cells (Figs 3 and 4) can best be explained by masking of NKG2D-mediated costi-
mulation, an effect imposed by the lower MHC-I surface level that came as unexpected
consequence of ULBP2 expression (Fig 5). It is long known that under conditions of low
MHC-I expression and limiting amounts of antigenic peptides, extensive activation of T cells
cannot occur [80]; in particular, when it comes to priming of naïve CD8+ T cells because they
have a higher activation threshold than memory or effector CD8+ T cells. Our data imply that
precisely in this setting when only low peptide concentrations are present, costimulation via
NKG2D can secure the induction of specific T cells. This view is supported by the results of
our previous mouse studies, which indicated that immunization with MCMV strains express-
ing the mouse NKG2D ligand RAE-1γ provided stronger protective immunity than infection
with wild-type MCMV [15, 32]. It will be of interest to understand how NKG2D ligands influ-
ence MHC-I surface expression. Interestingly, a previous publication reported that expression
of the murine NKG2D ligand RAE-1ε in RMA cells decreases MHC class I expression as well
[81], suggesting that this is a more general phenomenon applying to different NKG2D ligands.
Unraveling the exact underlying mechanism is beyond the scope of this work and must be the
subject of further studies.
An excellent safety profile would increase the acceptance of a potential HCMV vaccine and
will be an important goal, particularly when vaccination of immunocompromised patients is
considered. Further attenuation can probably be achieved by deletion of additional genes for
the numerous viral immunomodulatory functions, although it has to be examined that this
does not go at the expense of reduced vaccination efficacy. Another option to increase safety is
the application of replication- and spread-deficient vaccine strains. Studies in the mouse
model revealed that such strains preserve the ability to stimulate CMV-specific T cell immu-
nity [82, 83], and in a guinea pig model of congenital CMV infection partial protection of pups
was observed following immunization with a non-infectious guinea pig CMV BAC DNA vac-
cine [84] or with a non-replication-competent virus [85]. We have recently pioneered the
development of conditional-replicating CMV strains [86], and this technique has already suc-
cessfully been used to generate a conditionally replicating HCMV vaccine candidate, which is
currently in phase 1 testing (ClinicalTrials.gov number, NCT01986010). The combination of
the superior immunization approach presented here in this study with the safety features of a
replication-deficient strain could lead to an HCMV vaccine that may even be safely applicable
to immunocompromised patients. Additional preclinical studies are therefore warranted to
further analyze the protective efficacy as well as the safety of such vaccination strategies against
HCMV, particularly when improved humanized mouse models become available, ultimately
paving the way for clinical trials.
Materials and Methods
Ethics statement
Buffy coat samples were obtained from the Institute for Transfusion Medicine at Hannover
Medical School from voluntary healthy blood donors with known HCMV serological status.
All materials and data were analyzed anonymously. All studies were performed in accordance
with guidelines on human cell research and the approval of the Hannover Medical School
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Ethics Review Board. All animal research protocols were approved by the authorized Ethics
Committee for Biomedical Research of the Clinical Hospital Rijeka and of the University of
Rijeka (Cl. 003-08/12-01/40; No. 2170-24-01-12-03) in accordance with the guidance of the
European Parliament (Directive 2010/63/EU) and Croatian Federal Law about animal protec-
tion (Official Gazette, 135/2006 and 47/2011).
Isolation and culture of cells
PBMC were purified from buffy coat samples obtained from healthy blood donors using stan-
dard Biocoll (Biochrom) density gradient centrifugation according to a published protocol
(Miltenyi Biotec). Cells were cryopreserved in fetal bovine serum (FBS) with 10% DMSO.
Before NK cell isolation or prior to setting-up co-cultures, PBMC were thawed and cultured
overnight with 500 IU/ml interleukin-2 (IL-2) (ImmunoTools) in X-VIVO 15 medium
(Lonza) supplemented with 10% FBS and 5% human serum (inactivated at 56˚C; Sigma
Aldrich). Individual cell subsets (CD56+ NK cells, CD8+ T cells and CD14+ monocytes) were
isolated using human cell isolation kits (Miltenyi Biotec). NK cells were negatively selected,
while CD8+ T cells and monocytes were positively selected. Purity of selection was analyzed by
flow cytometry and was more than 94%. The pp65-specific T cell clone (CMV-CTL; kindly
provided by L. Hambach) was thawed 2 days before setting up assays in MEM-alpha medium
(Lonza) supplemented with 120 IU/ml of IL-2 and 10% human serum. The CMV-CTL was
tested for the absence of mycoplasma and its specificity was determined by intracellular cyto-
kine staining and proliferation assays using pp65-peptide loaded cells as positive control.
Human monocyte-derived dendritic cells (DC) were generated using a standard protocol [87].
Briefly, isolated monocytes were cultured for 5 days in X-VIVO 15 medium supplemented
with recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) and interleu-
kin-4 (IL-4) (50 ng/ml each; ImmunoTools). After 5 days, DC were used for infection or were
matured for 24 h by supplementing the medium with maturation cocktail: recombinant
human TNF-α (200 IU/ml), IL-1β (5 ng/ml), IL-6 (10 ng/ml), Prostaglandin E2 (1 μg/ml)
(ImmunoTools). Two hours before establishing co-cultures with PBMC or CD8+ T cells,
mature DC were loaded with a peptide pool spanning the entire CMV pp65 antigen (20 μg/ml;
JPT Peptide Technologies). Primary human foreskin fibroblasts (HFF) were generated follow-
ing standard methods as described [88] and were maintained in DMEM containing 10% FBS,
penicillin (100 units/ml), streptomycin sulfate (100 μg/ml), and 2 mM L-glutamine.
Viruses and infections
For the generation of the recombinant ULBP2-TB40 virus the ULBP2 ORF was amplified
using primers 5´-GTCGGTACCGTCGCAGTCTTCGGTCTGACCACCGTAGAACGAGA
GCTCCACCATGGCAGCAGCCGCCGCTACC-3´ and 5´-CCCGGATCCCTCTCCTCAGA
TGCCAGGGAGGATGAAG-3´ and an ULBP2 cDNA clone (Open Biosystems; Genbank
accession number: BC034689), and was cloned (via KpnI and BamHI) between the MCMV
major immediate-early promoter sequence (corresponding to nucleotides 182849 to 183094 of
the MCMV Smith Strain (Genbank accession number NC004065.1)) and a kanamycin resis-
tance (KanR) cassette flanked by FRT sites. The whole insert was amplified with primers 5´-G
ACACCGGGCTCCATGCTGACGTAGGTACCGACTGGGGTCAAAAGCCTTTAAACGG
TACTTTCCCATAGC-3´ and 5´-CTTATAGCAGCGTGAACGTTGCACGTGGCCTTTGC
GGTTATCCGTTCAGGAACACTTAACGGCTGA-3´, and inserted into the BAC-cloned
genome of the HCMV strain TB40/E [36] by red-α, -β, -γ-mediated recombineering as
described previously [89] replacing ORF UL16. The KanR cassette was excised by FLP recom-
binase. Correct insertion was verified by restriction analysis (BglII and NotI) and sequencing
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(with primers 5´-GGCGATGCGGTATCGCGCACA-3´ and 5´-GACACCTGTTCGTCCAG
AATC-3´). The mutant lacking ORF UL16 that was derived from the BAC-cloned TB40/E
strain was described previously [41]. All virus stocks were produced by propagation on HFF.
Briefly, supernatant was harvested at day 6 p.i., and virus was pelleted by ultracentrifugation
(100,000 × g, 1 h) and finally resuspended in X-VIVO 15 medium. Viral titers were deter-
mined using standard plaque assay on HFF. DC and fibroblasts were infected at an MOI of 3
and 1, respectively, followed by centrifugal enhancement (800 × g, 30 min).
NK cell cytotoxicity assay
HFF were infected with TB40 or ULBP2-TB40 as described above. One day p.i. the infection
rate of the HFF was determined by flow cytometry following intranuclear staining with an
Alexa Fluor 488-conjugated CMV IE1/2 antibody (Merck Millipore). Cells were cryopreserved
and thawed at the day of establishing the cytotoxicity assay. Prior establishing co-cultures, cells
were labeled with carboxyfluorescein succinimidyl ester (CFSE; eBioscience) and co-cultured
with freshly isolated human NK cells at effector to target ratios of 16:1, 8:1 and 4:1 in X-VIVO
15 medium supplemented with 500 IU/ml IL-2. After 4 h incubation at 37˚C, specific lysis was
determined by flow cytometry as measured by determination of dead cells using the Fixable
Viability Kit (L/D) (BioLegend). To evaluate the spontaneous death of cells, samples contain-
ing target cells only were used. Cytolytic activity of NK cells expressed as percentage of specific
lysis was determined by the following calculation: (% CFSE+ L/D+ cell specific lysis—% CFSE+
L/D+ cell spontaneous lysis) / (100 - % CFSE+ L/D+ cell spontaneous lysis) × 100.
Focus expansion assay
Focus expansion assays were established as previously described [41]. Briefly, infected HFF (10
cells/well; 3 d p.i.) were co-cultured with uninfected HFF (2 × 104 cells/well). NK cells were
added at the ratio 1:0.25 (HFF:NK cells). After 3 days, the cultures were fixed with 80% acetone,
and stained with the IE1/2 antibody. Infected cells per focus of infection and number of infectious
foci were counted using fluorescence microscopy. Each sample was performed in quadruplicates.
Antibody blocking
Blocking of NKG2D of human NK cells in vitro was performed using the NKG2D-specific
antibody clone 1D11 and isotype control mouse IgG1 (BioLegend) (both at 10 μg/ml). In addi-
tion, human Fc Block (25 μg/ml; BD Biosciences) was added.
T cell expansion and intracellular cytokine staining assays
For expansion of CMV-specific T cells, CD8+ T cells (105 cells/well) isolated from
HLA-A02:01 HCMV-seropositive healthy donors were co-cultured with autologous mono-
cyte-derived DC (uninfected, infected with respective viruses or mature peptide-loaded) and
with γ-irradiated autologous CD14- feeder cells (2–3 × 105 cells/well). Co-cultures were set up
in 96-well plates at the ratio 1:10 (DC:T cell) in X-VIVO 15 medium supplemented with 5%
human serum and IL-2 (500 IU/ml), IL-7 and IL-15 (10 ng/ml each; ImmunoTools). Every 2
days fresh medium containing cytokines was replenished. After 7 days, expanded cells were
transferred to 48-well plates, and freshly prepared DC and feeder cells were added. After 2
weeks, the percentage of pp65-specific CD8+ T cells was determined by flow cytometry follow-
ing staining with the PE-conjugated tetramer HLA-A02.01-NLVPMVATV (MoBiTec). For
intracellular cytokine staining, the expanded T cells, PBMC or the pp65-specific CTL clone
were stimulated in 96-well V-bottom plates for 6 h with DC loaded with the pp65 peptide pool
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or the NLVPMVATV peptide or with uninfected/infected DC for PBMC and the pp65-specific
T cell clone (at a ratio 1:10 [DC:T cells]). Protein transport inhibitor cocktail and a PE-Cy7-con-
jugated antibody against CD107a (clone H4A3; Biolegend) were added at the beginning of the
assay. For surface staining we used PerCp-Cy5.5-conjugated anti-human CD3 (clone OKT3;
eBioscience), PE-Texas Red-conjugated anti-human CD8 (clone 3B5; Thermo Fisher Scientific)
and in case of expanded T cells additionally the PE-conjugated tetramer HLA-
A02:01-NLVPMVATV. After fixation with 3% paraformaldehyde for 5 min at RT and permea-
bilization with 0.1% saponin for 20 min at RT, FITC-conjugated (for expanded T cells) or PE-
conjugated anti-human IFNγ (clone 4S.B3; eBioscience) and APC-conjugated anti-human
TNFα Abs (clone Mab11; eBioscience) were used for staining. One million of splenocytes iso-
lated from humanized mice were incubated with 1 μg of the peptide 316-VLEETSVML-324
(HLA-A2 restricted immunodominant epitope from the CMV IE1 antigen) for 5 h at 37˚C, with
brefeldin A (eBioscience) added for the last 4 h of stimulation. For evaluation of IFNγ produc-
tion by NK cells, 5 × 106 splenocytes were resuspended in 400 μl of RPMI medium supplemented
with 10% FCS and IL2 (500 U/ml) and cultured for 5 h at 37˚C in the presence of brefeldin A.
Engraftment and infection of NSG-HLA-A2 mice
Humanization of mice was performed at the Helmholtz Center for Infection Research (Braun-
schweig, Germany). Briefly, fetal liver mononuclear cells were isolated over Ficoll-density gradi-
ents, and CD38- CD34+ cells were enriched using a MACS selection kit (Miltenyi Biotec).
Newborn (3–5 days old) NOD.Cg-Prkdcscid Il2rgtm1WjlTg(HLA-A2.1)1Enge/SzJ mice expressing
human HLA-A02:01 (NSG-A2) were irradiated with 0.7 Gy and 4–6 h after irradiation injected
with 1 × 105 CD34+ cells intrahepatically. 3 months post transfer engraftment of human cells
was determined in blood. Humanization status ranged from 70–90% of human leukocytes
(hCD45+ cells). Animals were randomly assigned to experimental groups with the humaniza-
tion status being equal among the experimental groups. Mice were injected intraperitoneally
with uninfected or TB40 or ULBP2-TB40 infected DC (3 × 105 cells/mouse) generated from
monocytes of HLA-A02:01 positive HCMV seronegative donors. Mice were daily treated with
subcutaneous injections of recombinant human granulocyte colony-stimulating factor (G-CSF)
(3.6 μg/mouse s.c.; Filgrastim HEXAL). Mice were boosted after 7 days with freshly prepared,
uninfected or infected DC (3 × 105 cells/mouse).
Detection of CMV-specific IgM by ELISA
Analysis of CMV-specific IgM antibodies in serum of infected animals was performed using
anti-CMV IgM Human in vitro ELISA kit (Abcam) according to the manufacturer’s instruc-
tions. Briefly, a 96-well plate was precoated with CMV antigens to bind cognate antibodies.
Control and test samples were added to the wells in duplicates. Serum was isolated from blood
using density gradient centrifugation applying the standard PBMC isolation protocol (Milte-
nyi Biotec) and stored at -20˚C. The following controls were included: CMV IgM positive con-
trol, CMV IgM negative control and CMV IgM cut-off calibrator. Following washing, a
horseradish peroxidase (HRP) labelled anti-human IgM conjugate was added to the wells and
after incubation as according to the instructions of the manufacturer, the reaction was stopped
by adding an acidic stop solution. Absorbance at 450 nm was measured immediately using a
TriStar Version 1.04 microplate reader (BertholdTech).
Histology and immunohistochemistry
Sections from formalin fixed, paraffin-embedded spleens were stained with hematoxylin and
eosin. Labelling of tissue sections was performed by an anti-human CD3 (F7.2.38) Ab (Dako)
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followed by biotinylated goat anti-mouse IgG (BD Pharmingen), streptavidin covalently cou-
pled to horseradish peroxidase conjugate (Roche Applied Science) and DAB chromogene
(Dako). Slides were examined with an Olympus BX51 microscope, images were acquired by
an Olympus digital camera (DP71) and analyzed using Cell^B software.
Quantitative PCR analysis of HCMV DNA
DNA was isolated from spleen, liver, bone-marrow, blood and salivary glands using the Relia-
Prep Blood gDNA Miniprep Kit (Promega) according to the manufacturer’s protocol. Pres-
ence of HCMV DNA was determined by 7500 Fast Real-Time PCR system (Applied
Biosystems) using a predefined two step PCR: 1 cycle at 95˚C for 15 min followed by 40 cycles
at 95˚C for 15 s and 60˚C for 1 min using Power SYBR Green PCR master mix and TaqMan
Universal PCR mix (Applied Biosystems). To detect viral DNA primers specific for gB (gB_Fw
5’-AGG TCT TCA AGG AAC TCA GCA AGA and gB_Rv 5’-CGG CAA TCG GTT TGT
TGT AAA) and a TaqMan gB probe with TAMRA quencher (6FAM—AAC CCG TCA GCC
ATT CTC TCG GC—TAMRA) was used as previously described [90]. For the standardization
curve we used the gB and IE1-TOPO TA pCR2.1 plasmid (kindly provided by S. Boppana;
University of Alabama, Birmingham, AL).
Flow cytometry
For flow cytometry analysis the following antibodies were used: anti-human Alexa Fluor
700-conjugated CD80 (L307.4; BD Biosciences), Brilliant Violet 510 conjugated CD86 (IT2.2;
BioLegend), PE-conjugated CD209 (5H10; eBioscience), PE-Cy7-conjugated CD14 (61D3;
eBioscience), PE-CF594-conjugated HLA-DR (G46-6; BD Biosciences), APC- -conjugated
CD3 (OKT3; eBioscience), Alexa Fluor780-conjugated CD8 (SK1; conjugated HLA-ABC
(W6/32; eBioscience), BV510-conjugated CD1a (HI149; BD Biosciences), APC-conjugated
HLA-A2 (BB7.2; eBioscience), PE-conjugated ULBP2/5/6 (165903; R&D Systems), APC
eBioscience), PE-Cy7–conjugated CD19 (HIB19; eBioscience), PE-conjugated CD56 (CMSSB;
eBioscience), APC-conjugated PD-1 (MIH4; eBioscience), FITC-conjugated CD57 (TB01;
eBiosceince), FITC-CD45RA (HI100; eBioscience), PE-Cy7-CCR7 (3D12; eBioscience),
PE-Cy7-CD62L (DREG-56; eBioscience) and FITC-CD45RO (UCHL1; eBioscience). As iso-
type controls we used PE-conjugated mouse IgG2a (R&D Systems) and APC-conjugated
mouse IgG2b (eBioscience). For dead cells exclusion Zombie NIR Fixable Viability Kit (BioLe-
gend) was used. Intranuclear staining with an Alexa Fluor 488-conjugated IE1/2-specific anti-
body (Merck Millipore) after PFA fixation and permeabilization with 75% ice-cold ethanol
was used to detect infected cells. For evaluation of the phenotype of CD8+ T cell we used anti-
human APC-conjugated NKG2D (1D11; eBioscience). CMV-specific CD8+ T cells from
blood and spleen of humanized mice were analyzed on days 14 and 18 p.i, respectively, using
the PE-conjugated pp65-specific tetramer HLA-A02.01-NLVPMVATV and the APC-conju-
gated IE1-specific tetramer HLA-A02:01- VLEETSVML synthesized by the NIH tetramer
core facility. Flow cytometry was performed using FACSVerse, FACSAria or LSRII (BD Bio-
sciences), and data were analyzed using FlowJo software (Tree Star).
Statistical analyses
Statistical analyses were performed with GraphPad Prism5 software and statistical tests used
are indicated in the figure legends. No statistical method was used to predetermine sample
size, and data analysis was not blinded. Exact sample sizes and number of independent experi-
ments performed are indicated in each figure legend. No samples were excluded. All error bars
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represent SEM or range as noted in the figure legends. Differences were considered to be sta-
tistically significant for P values<0.05.
Supporting Information
S1 Fig. Insertion of the ULBP2 gene does not affect replication of the ULBP2-TB40 virus
in vitro. HFF were infected with 1 PFU per cells with TB40 (black) and ULBP2-TB40 (red)
viruses. At indicated time points supernatants were harvested, and viral titers were determined
by plaque assay. The values at day 0 represent the inocula.
(PDF)
S2 Fig. NK cells decrease the number of infectious foci per well in cultures with
ULBP2-TB40 infected cells. Focus expansion assays were set up using TB40 or ULBP2-TB40
infected HFF and primary NK cells of 6 donors as described in Fig 1E. A focus of infection was
defined as a cluster of at least 3 and not more than 60 infected cells. Each donor was analyzed
in quadruplicates. Results are mean numbers of infectious foci per well ±SEM.
(PDF)
S3 Fig. Percentage and phenotype of NK cells in humanized mice. Humanized mice were
treated as described in Fig 2. (A) Percentage of CD56+ NK cells out of the total CD3-negative
cell population (CD3-CD19-) in livers for the respective groups. Each circle represents the
result for one animal; horizontal bars indicate medians. (B, C) Percentage of CD57+ (B) and
IFNγ+ NK cells (C) in spleens of animals from the indicated groups. Differences between the
groups were analyzed by Mann-Whitney t-test. , P < 0.05; not significant (ns), P> 0.05.
(PDF)
S4 Fig. Infected DC led to the priming of HCMV-specific CD8+ T cells in humanized
mice. Immunization was performed with TB40 or ULBP2-TB40-infected DC in humanized
mice (as described in Fig 2). Dot plots indicate staining of IE1-tetramer+ lymphocytes
(IE1-tet) isolated from blood of 3 animals from each group 2 weeks after immunization. Per-
centages of IE1 (upper graph) and pp65-specific CD8+ T cells (lower graph) for animals of the
groups receiving DC infected with the respective viruses. Differences between the groups were
not significant as analyzed by Mann-Whitney t-test. ns, P > 0.05.
(PDF)
S5 Fig. Functionality and phenotype of antigen-specific CD8+ T cells. Humanized mice
were injected with infected DCs as described in Fig 2. (A) On day 18 p.i. the frequency of
IE1-specific CD8+ T cells was analyzed by IE1-tetramer staining of splenocytes derived from
animals of the respective groups. Representative staining for cells of one animal analyzed from
each group. Graph at right provides the compiled data for IE1-tetramer+ CD8+ T cells in
spleen of animals for the indicated groups. (B) Intracellular cytokine staining to evaluate per-
centage of IFNγ-positive CD8+ T cells after 6 h stimulation with the IE1 peptide. Graph shows
cumulative data for IFNγ-positive CD8+ T cells from the indicated groups. (C) Percentage of
naive (CD62L+CD45RO-) and terminally differentially effector memory (TEMRA;
CD62L-CD45RO-) CD8+ T cell subsets in spleen from animals in the indicated. Data were
analyzed with Mann-Whitney t-test. ns, P> 0.05.
(PDF)
S6 Fig. Expansion of pp65-specific CD8+ T cells using peptide loaded mature DC as posi-
tive control. Representative dot plots depicting percentages of pp65-specific CD8+ T cells
from one donor before expansion and after 14 days of co-culture with uninfected autologous
DC or pp65-peptide loaded mature DC (pp65-mDC). Lower plots, staining with irrelevant
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tetramer as negative control (irrel-tet). The graph at right is compiled data from 4 donors.
Horizontal bars are medians. Data are representative for one of two independent experiment
performed.
(PDF)
S7 Fig. Phenotype of expanded T cells. Representative dot plots of an experiment performed
with cells from one donor indicating percentage of naive (N; CCR7+CD45RA+), central mem-
ory (CM; CCR7+CD45RA-), effector memory (EM; CCR7-CD45RA-) and terminally differen-
tiated effector memory (TEMRA; CCR7-CD45RA+) CD8+ T cells before expansion and after
14 days of co-culture with TB40 or ULBP2-TB40 infected DC. Graphs display compiled data
for four donors as percentages of (A) CM or EM CD8+ T cells and (B) CM or
EM pp65-specific CD8+ T cells expanded with TB40 (black circles), ULBP2-TB40 (red circles)
infected DC or pp65-peptide loaded DC (grey circles). (C, D) Percentage of PD-1+ CD8+ T
cells (C) and PD1+ pp65-specific CD8+ T cells (D). Data obtained with cells from individual
donors are connected by lines. Data are representative of one of two independent experiment
performed. Statistical analysis was done with one-way ANOVA Friedman test followed by
Dunn’s Multiple Comparison test. , P< 0.05; ns, P > 0.05.
(PDF)
S8 Fig. CD4 T cell responses in PBMC stimulation assay. (A) Percentage of IE1/2-positive
DC 1 day after infection with 3 PFU per cell of TB40 (black circles) and ULBP2-TB40 (red cir-
cles). Compiled data for DC of four donors are given, horizontal bars represent medians. (B,
C) Intracellular cytokine staining for IFNγ (B) and TNFα (C) expression of CD4 T cells (CD3
+CD8-) upon co-cultivation of PBMC with autologous monocyte-derived DC that remained
uninfected or were infected as indicated. Graphs are compiled data of experiments performed
with cells of 4 HCMV-seropositive donors. Data generated with cells of individual donors are
connected by lines and are representative of one of three independent experiment performed.
Statistical analysis was done with one-way ANOVA Friedman test followed by Dunn’s Multi-
ple Comparison test. , P < 0.05; ns, P> 0.05.
(PDF)
S9 Fig. Maturation phenotype of infected DC. (A) Representative staining for CD80, CD86
and HLA-DR expression on TB40 or ULBP2-TB40 infected DC (IE1/2-positive cells) and on
uninfected DC matured as described in Materials and Methods. Graphs at right provide com-
piled data for DC of 6 donors. Results obtained with DC of one donor are connected by lines.
(B) Median fluorescence intensity (MFI) of CD80, CD86 and HLA-DR for TB40 (black circles)
and ULBP2-TB40 (red circles) infected DC relative to MFI values of uninfected DC in the
same cultures (IE1/2-negative bystander cells) (n = 6 donors). Horizontal bars represent medi-
ans. Representative experiment of two of seven independent experiments performed. Data
were analyzed using one-way ANOVA Friedman test followed by Dunn’s Multiple Compari-
son test. P < 0.05; ns, P > 0.05.
(PDF)
S10 Fig. Stimulation of pp65-specific T cells by ULBP2-expressing HCMV-infected DC
leads to NKG2D downregulation. pp65-specific CD8+ T cells were obtained by co-culturing
CD8+ T cells from HLA-A2+, HCMV seropositive donors with pp65-peptide loaded autolo-
gous DC as described in Materials and Methods. Representative plots of pp65-specific CD8+ T
cells (derived from one donor) after co-culturing with autologous uninfected DC or DC
infected with the indicated viruses show (A) IFNγ, TNFα and CD107a intracellular staining
and (B) NKG2D surface expression. Similar data were obtained using cells derived from three
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different donors.
(PDF)
S11 Fig. CD8+ T cells expanded with HCMV infected DC express NKG2D. (A) Histograms
depict NKG2D expression on CD8+ T cells from one donor before expansion and after 2
weeks of co-culture with uninfected, TB40 or ULBP2-TB40 infected DC or pp65-peptides
loaded mature DC (pp65-mDC). Black lines indicate staining with isotype antibody. (B) Com-
piled data depicting percentages of NKG2D positive CD8+ T cells from 4 donors before expan-
sion and after expansion with the different DC. Data obtained with cells from one donor are
connected by lines.
(PDF)
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